Science Explorer Back to mapMap
Discussion
Institution · Theageneio General Hospital

Most cited papers from Theageneio General Hospital

Theageneio General Hospital

What are the most cited papers from Theageneio General Hospital?

The most cited paper from Theageneio General Hospital is "Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis" (George V. Papanikolaou et al., 2003), with 985 citations. Next come "Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis" (866) and "Applied Incremental Dynamic Analysis1" (649).

Showing 50 of 60 papers. Every paper with more than 105 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis George V. Papanikolaou et al. · Nature Genetics 30 Nov 2003 985
2 Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis Antonella Roetto, George V. Papanikolaou, Marianna Politou et al. · Nature Genetics 9 Dec 2002 866
3 Applied Incremental Dynamic Analysis1 Dimitrios Vamvatsikos, C. Allin Cornell · Earthquake Spectra May 2004 649
4 Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma Pieter Sonneveld et al. · New England Journal of Medicine Open access 12 Dec 2023 574
5 Hepcidin in iron overload disorders George V. Papanikolaou, Michalis Tzilianos, John I. Christakis et al. · Blood Open access 30 Jan 2005 447
6 Assessment of Depression and Anxiety in Breast Cancer Patients: Prevalence and Associated Factors Konstantinos Tsaras, Ioanna V. Papathanasiou, Dimitra Mitsi et al. · PubMed Open access 25 Jun 2018 440
7 Soluble receptor activator of nuclear factor κB ligand–osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index Evangelos Terpos, Richard Szydlo, Jane F. Apperley et al. · Blood 15 Apr 2003 414
8 FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) John Souglakos, Nicos Androulakis, Konstantinos N. Syrigos et al. · British Journal of Cancer Open access 28 Feb 2006 405
9 Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells Matthew J. Grimshaw, Lucienne Cooper, Konstantinos T Papazisis et al. · Breast Cancer Research Open access 9 Jun 2008 343
10 Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial Meletios Athanasios Dimopoulos et al. · The Lancet Oncology Open access Jun 2021 340
11 Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial Sebastian Grosicki et al. · The Lancet Open access Nov 2020 339
12 The diagnosis and management of malignant phaeochromocytoma and paraganglioma Alexandra Chrisoulidou, Gregory Kaltsas, Ioannis Ilias et al. · Endocrine Related Cancer Sep 2007 316
13 Optimization of the sulforhodamine B colorimetric assay Konstantinos T Papazisis, George D. Geromichalos, Konstantinos A. Dimitriadis et al. · Journal of Immunological Methods Oct 1997 313
14 Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single‐centre experience in 303 patients Kostas Zervas, Evgenia Verrou, Zisis Teleioudis et al. · British Journal of Haematology 2 Aug 2006 298
15 Thalidomide and dexamethasone combination for refractory multiple myeloma Meletios Athanasios Dimopoulos, Konstantinos Zervas, G. Kouvatseas et al. · Annals of Oncology Open access Jul 2001 284
16 Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance V. Eleutherakis-Papaiakovou, Aristotelis Bamias, Dimitra Gika et al. · Leukemia & lymphoma/Leukemia and lymphoma 2007 233
17 Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis on behalf of the Hellenic Sepsis Study Group et al. · BMC Medicine Open access 15 Sep 2017 224
18 Total and High-Molecular-Weight Adiponectin in Breast Cancer:In Vitroandin VivoStudies Antje Körner, Kalliopi Pazaitou‐Panayiotou, Theodoros Kelesidis et al. · The Journal of Clinical Endocrinology & Metabolism 28 Dec 2006 224
19 Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study Timo Deutschbein et al. · The Lancet Diabetes & Endocrinology Open access 6 May 2022 197
20 Extrapelvic endometriosis: a rare entity or an under diagnosed condition? Nikolaos Machairiotis, Aikaterini Stylianaki, Georgios Dryllis et al. · Diagnostic Pathology Open access Dec 2013 197
21 Pneumothorax after transthoracic needle biopsy of lung lesions under CT guidance. Tatjana Bošković, Jelena Stanić, Slobodanka Pena-Karan et al. · PubMed Open access Mar 2014 196
22 Saffron as a Source of Novel Acetylcholinesterase Inhibitors: Molecular Docking and in Vitro Enzymatic Studies George D. Geromichalos, Fotini N. Lamari, Magdalini A. Papandreou et al. · Journal of Agricultural and Food Chemistry Jun 2012 187
23 Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG) Efstathios Kastritis, Konstantinos Zervas, Argiris S. Symeonidis et al. · Leukemia 19 Feb 2009 187
24 Right heart failure post left ventricular assist device implantation. Mihalis Argiriou, Styliani-Maria Kolokotron, Timothy Sakellaridis et al. · PubMed Open access Mar 2014 171
25 Pneumomediastinum. Vasileios K. Kouritas, Konstantinos Papagiannopoulos, George Lazaridis et al. · PubMed Open access Feb 2015 168
26 Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG) D. Mavroudis, Emmanouil S. Saloustros, Nicholaos A. Malamos et al. · Annals of Oncology Open access 2 May 2015 165
27 Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): current literature review. Antonis Papaiwannou, Paul Zarogoulidis, Konstantinos Porpodis et al. · PubMed Open access Mar 2014 161
28 Anti-inflammatory drugs interacting with Zn(II), Cd(II) and Pt(II) metal ions C. Dendrinou-Samara, Georgia Tsotsou, Loucia V. Ekateriniadou et al. · Journal of Inorganic Biochemistry Sep 1998 157
29 Novel Cinnamic Acid Derivatives as Antioxidant and Anticancer Agents: Design, Synthesis and Modeling Studies Eleni A. Pontiki, Dimitra Hadjipavlou‐Litina, Κonstantinos E. Litinas et al. · Molecules Open access 7 Jul 2014 149
30 Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study Brian L. Bressler, Andres J. Yarur, Mark S. Silverberg et al. · Journal of Crohn s and Colitis Open access 25 Mar 2021 148
31 High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents Evangelos Terpos, Eirini Katodritou, Μαρία Ρούσσου et al. · European Journal Of Haematology 6 May 2010 148
32 Thyroid Cancer in Patients with Hyperthyroidism Kalliopi Pazaitou‐Panayiotou, Konstantinos Michalakis, Ralf Paschke · Hormone and Metabolic Research Open access 14 Feb 2012 148
33 Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity Marco Capezzone, Stefania Marchisotta, Silvia Cantara et al. · Endocrine Related Cancer Open access 10 Sep 2008 147
34 Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma Ashraf Z. Badros, Evangelos Terpos, Eirini Katodritou et al. · Journal of Clinical Oncology Open access 18 Nov 2008 145
35 In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2 Ken Maes, Elizabeta Nemeth, G. David Roodman et al. · Blood Open access 2 Aug 2010 139
36 Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations Georgios Tsaousis et al. · BMC Cancer Open access 3 Jun 2019 138
37 Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals Christos Magopoulos, Georgios Karakinaris, Zisis Telioudis et al. · American Journal of Otolaryngology May 2007 138
38 Localized B-cell non-Hodgkin's lymphoma of oral cavity and maxillofacial region: A clinical study Alexandros E. Kolokotronis, Nikolaos Konstantinou, Ioannis A. Christakis et al. · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology 17 Feb 2005 137
39 Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study Efstathios Kastritis, Maria Gavriatopoulou, Marie‐Christine Kyrtsonis et al. · Blood Open access 10 Sep 2015 134
40 Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma Aristeidis Chaidos, Chris P. Barnes, Gillian Cowan et al. · Blood 21 Nov 2012 134
41 Pyogenic granuloma of the oral cavity: Comparative study of its clinicopathological and immunohistochemical features Apostolos Epivatianos, D. Antoniades, Thomas Zaraboukas et al. · Pathology International 27 Jun 2005 131
42 Platinum(II) and palladium(II) complexes with 2-acetylpyridine thiosemicarbazone: cytogenetic and antineoplastic effects Z. Iakovidou, Athanasios Papageorgiou, M.A. Demertzis et al. · Anti-Cancer Drugs 2001 127
43 Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients Ioannis Boukovinas, Chara Papadaki, Pedro Méndez et al. · PLoS ONE Open access 10 Nov 2008 125
44 Cutaneous squamous cell carcinoma (SCC) of the head and neck: Risk factors of overall and recurrence-free survival Athanassios Kyrgidis, Thrasyvoulos Tzellos, Nikolaos Kechagias et al. · European Journal of Cancer Open access 25 Mar 2010 124
45 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care Theodoros P. Vassilakopoulos et al. · The Oncologist Open access 26 Jan 2012 124
46 Airway inflammation in chronic obstructive pulmonary disease. Nikolaos Angelis, Konstantinos Porpodis, Paul Zarogoulidis et al. · PubMed Open access Mar 2014 124
47 Adiponectin: a link between obesity and cancer Diana Barb, Kalliopi Pazaitou‐Panayiotou, Christos Socrates Mantzoros · Expert Opinion on Investigational Drugs 21 Jul 2006 123
48 In vitro application of Fe/MgO nanoparticles as magnetically mediated hyperthermia agents for cancer treatment Anastasia Chalkidou, K. Simeonidis, Mavroeidis Angelakeris et al. · Journal of Magnetism and Magnetic Materials 12 Nov 2010 120
49 Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease G. E. Krassas, Argyrios Dumas, N. Pontikldes et al. · Clinical Endocrinology Jun 1995 118
50 Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine John Souglakos, Ioannis Boukovinas, Miquel Tarón et al. · British Journal of Cancer Open access 15 Apr 2008 117

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.